CTLA4 and melanoma: Our ICBcircSig score model is a highly robust predictor of the efficacy of immunotherapy in patients with melanoma, irrespective of whether they are undergoing anti-PD-1 treatment alone or combined anti-CTLA-4 and anti-PD-1 treatment.